By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left.
By Colin Kellaher American depositary shares of Mesoblast plummeted more than 65% in premarket trading Friday after the biopharmaceutical company's latest.
By Denny Jacob International stocks trading in New York closed mostly higher on Friday. The S&P/BNY Mellon index of American depositary receipts edged up.